Eton Pharmaceuticals' (ETON) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON - Free Report) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $33.00 price objective on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals' Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.18 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.57 EPS, FY2027 earnings at $1.85 EPS, FY2028 earnings at $2.87 EPS and FY2029 earnings at $3.74 EPS.

ETON has been the topic of a number of other research reports. B. Riley assumed coverage on Eton Pharmaceuticals in a report on Friday, January 10th. They issued a "buy" rating and a $21.00 target price on the stock. Craig Hallum raised their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, January 8th.

Eton Pharmaceuticals Price Performance

NASDAQ:ETON traded down $0.56 during trading hours on Wednesday, reaching $14.22. 223,652 shares of the company were exchanged, compared to its average volume of 159,818. The company has a market capitalization of $370.45 million, a P/E ratio of -64.64 and a beta of 1.37. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The business has a 50 day moving average of $15.58 and a 200 day moving average of $11.63.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). The firm had revenue of $11.65 million for the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, equities research analysts anticipate that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ETON. Point72 Asia Singapore Pte. Ltd. bought a new position in Eton Pharmaceuticals during the 3rd quarter worth $54,000. Tower Research Capital LLC TRC bought a new position in Eton Pharmaceuticals during the 4th quarter worth $86,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals during the 3rd quarter worth $90,000. Jefferies Financial Group Inc. bought a new position in Eton Pharmaceuticals during the 4th quarter worth $133,000. Finally, Raymond James Financial Inc. bought a new position in Eton Pharmaceuticals during the 4th quarter worth $147,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.